Published in Mol Cancer Ther on January 01, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 1.60
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One (2016) 1.41
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res (2013) 1.19
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J Exp Clin Cancer Res (2014) 1.12
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med (2012) 1.11
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A (2011) 1.09
In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res (2009) 1.09
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.08
Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice. Am J Pathol (2010) 1.06
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J (2013) 0.99
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs (2010) 0.97
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol (2010) 0.96
"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett (2014) 0.91
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer (2012) 0.88
Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest (2014) 0.87
Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res (2007) 0.86
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia (2013) 0.86
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol (2015) 0.85
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol (2013) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget (2015) 0.82
MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int (2013) 0.82
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget (2014) 0.81
[(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol (2016) 0.79
Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases. Cell Cycle (2012) 0.79
Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine. J Proteomics (2012) 0.79
Dynamics of elongation factor 2 kinase regulation in cortical neurons in response to synaptic activity. J Neurosci (2015) 0.77
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer J (2011) 0.77
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo. Carcinogenesis (2013) 0.77
Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. J Cancer (2015) 0.76
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci (2011) 0.75
Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition. Br J Pharmacol (2017) 0.75
Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress. PLoS One (2016) 0.75
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol (2016) 0.75
Perforation of the gastrointestinal tract secondary to ingestion of foreign bodies. World J Surg (2006) 4.71
The journal impact factor: too much of an impact? Ann Acad Med Singapore (2006) 2.98
CT in the preoperative diagnosis of fish bone perforation of the gastrointestinal tract. AJR Am J Roentgenol (2006) 2.54
Predictive factors of malignancy in adults with intussusception. World J Surg (2006) 2.37
A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg (2006) 2.15
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology (2014) 2.11
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Retroperitoneal schwannoma. Am J Surg (2006) 1.93
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: is limited resection appropriate? J Surg Oncol (2008) 1.77
The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci (2009) 1.62
Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer (2004) 1.60
A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res (2003) 1.60
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.57
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55
Are the Sendai and Fukuoka consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients. Ann Surg Oncol (2014) 1.54
Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res (2011) 1.49
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
Intra-abdominal and retroperitoneal lymphangiomas in pediatric and adult patients. World J Surg (2005) 1.44
Postoperative endocrine function in patients with surgically treated thyrotoxicosis. Head Neck (2004) 1.42
Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg (2006) 1.40
General Surgery (GS) Residency Selection Process: A Comparison Between Singapore (Singhealth) and United States. Ann Acad Med Singapore (2014) 1.38
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Nanoparticles in photodynamic therapy. Chem Rev (2015) 1.26
Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol (2005) 1.24
Pancreatic serous oligocystic adenomas: clinicopathologic features and a comparison with serous microcystic adenomas and mucinous cystic neoplasms. World J Surg (2006) 1.24
Intraabdominal schwannomas: a single institution experience. J Gastrointest Surg (2007) 1.23
A single-institution experience with eight CD117-positive primary extragastrointestinal stromal tumors: critical appraisal and a comparison with their gastrointestinal counterparts. J Gastrointest Surg (2009) 1.20
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
Solid pseudopapillary neoplasms of the pancreas: an updated experience. J Surg Oncol (2007) 1.18
Investigation of meticillin-resistant Staphylococcus aureus in pigs used for research. J Med Microbiol (2007) 1.16
Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology (2006) 1.15
Impact of the introduction of laparoscopic wedge resection as a surgical option for suspected small/medium-sized gastrointestinal stromal tumors of the stomach on perioperative and oncologic outcomes. World J Surg (2010) 1.14
A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach. Ann Surg Oncol (2013) 1.13
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol (2009) 1.12
Retroperitoneal liposarcomas: the experience of a tertiary Asian center. World J Surg Oncol (2011) 1.10
How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant or malignant cystic lesions of the pancreas? Results from a single institution experience with 220 surgically treated patients. J Am Coll Surg (2007) 1.09
Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res (2006) 1.07
A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ (2002) 1.07
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther (2009) 1.07
Head & neck optical diagnostics: vision of the future of surgery. Head Neck Oncol (2009) 1.05
Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep (2004) 1.04
Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol (2008) 1.02
Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res (2005) 1.02
Pancreatic adenocarcinoma that mimics groove pancreatitis: case report of a diagnostic dilemma. Dig Dis Sci (2006) 1.02
Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model. PLoS One (2008) 1.01
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther (2007) 1.00
Primary malignant melanoma of the esophagus with multiple esophageal lesions. Nat Clin Pract Gastroenterol Hepatol (2007) 1.00
Posterior perforation of peptic ulcers: presentation and outcome of an uncommon surgical emergency. Surgery (2004) 0.98
Cancer trends and incidences in Singapore. Jpn J Clin Oncol (2013) 0.97
Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma. Genes Chromosomes Cancer (2008) 0.95
Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles. Int J Nanomedicine (2007) 0.95
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther (2007) 0.95
Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer (2005) 0.94
Radiation dermatitis following radioembolization for hepatocellular carcinoma: a case for prophylactic embolization of a patent falciform artery. J Vasc Interv Radiol (2009) 0.93
Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis (2011) 0.93
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther (2009) 0.93
Pancreatic cysts: a proposed management algorithm based on current evidence. Am J Surg (2007) 0.93
Non-neoplastic cystic and cystic-like lesions of the pancreas: may mimic pancreatic cystic neoplasms. ANZ J Surg (2006) 0.92
A comparison of imaging techniques to monitor tumor growth and cancer progression in living animals. Int J Mol Imaging (2011) 0.92
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore (2013) 0.92
A global partnership in medical education between Duke University and the National University of Singapore. Acad Med (2008) 0.91
The use of digitized endoscopic imaging of 5-ALA-induced PPIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo. Int J Cancer (2004) 0.91
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol (2011) 0.90
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer (2009) 0.90
Oligodendrocytes regulate formation of nodes of Ranvier via the recognition molecule OMgp. Neuron Glia Biol (2006) 0.90
Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. J Gynecol Oncol (2011) 0.90
Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT. J Photochem Photobiol B (2005) 0.89
Severe acute respiratory syndrome: clinical outcome after inpatient outbreak of SARS in Singapore. BMJ (2003) 0.89
Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. Eur J Pharm Biopharm (2008) 0.88
Novel photodynamic diagnosis of bladder cancer: ex vivo fluorescence cytology using hypericin. Int J Oncol (2003) 0.87
Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg (2014) 0.87
Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg (2010) 0.87
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int J Mol Med (2005) 0.86
Hepatic angiomyolipoma mimicking hepatocellular carcinoma. Asian J Surg (2002) 0.86
2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link? Ann Acad Med Singapore (2012) 0.86
Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res (2008) 0.85
Optimal excitation-emission wavelengths for autofluorescence diagnosis of bladder tumors. Int J Cancer (2003) 0.85
Outcome of distal pancreatectomy for pancreatic adenocarcinoma. Dig Surg (2008) 0.85
Surgical management of endoscopic retrograde cholangiopancreatography-related perforations. ANZ J Surg (2003) 0.85
Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years. J Gastrointest Surg (2009) 0.85
Confocal endomicroscopic imaging of normal and neoplastic human tongue tissue using ALA-induced-PPIX fluorescence: a preliminary study. Oncol Rep (2004) 0.85
Titania coated upconversion nanoparticles for near-infrared light triggered photodynamic therapy. ACS Nano (2015) 0.85
Metastatic lung cancer causing bowel perforations: spontaneous or chemotherapy-related? ANZ J Surg (2002) 0.84
The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res (2004) 0.84
Factors associated with and outcomes of open conversion after laparoscopic minor hepatectomy: initial experience at a single institution. Surg Endosc (2014) 0.84
Outcome after curative resection of large (>or=10 cm) gastric gastrointestinal stromal tumors: how frequent is adjacent organ involvement and is concomitant distal pancreatectomy necessary? J Gastrointest Surg (2010) 0.83
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. Mol Cell Biol (2012) 0.83
Photolon™ --photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Int J Oncol (2011) 0.83
Infected pancreatic necrosis--an evaluation of the timing and technique of necrosectomy in a Southeast Asian population. Ann Acad Med Singapore (2006) 0.82